Phase 2 Leukaemia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with AML (a type of blood cancer) that has either not responded to treatment or has come back, OR you have been diagnosed with MDS (a bone marrow disorder) with at least 5% abnormal cells in your bone marrow
- You are generally well enough to carry out light activity and care for yourself (this is measured on a standard 0–1 scale used by doctors)
- You have a sufficient level of certain white blood cells in your blood
- Your kidneys, liver, and heart are working well enough to meet specific medical thresholds (confirm with trial site)
- If you are a woman who could become pregnant, you must have a negative pregnancy test before joining
- Both men and women who could have children must agree to use an effective form of birth control during the trial
- You are able to understand and sign a consent form agreeing to take part
Who may not be able to join:
- You have a specific type of leukemia called acute promyelocytic leukemia (APL)
- You have an active and significant condition affecting your brain or nervous system
- You have an autoimmune disease (where your immune system attacks your own body) that requires medication to suppress your immune system
- You have been diagnosed with severe liver scarring (a condition called hepatic bridging cirrhosis)
- You currently have an active hepatitis B or C infection
- You have previously received a gene therapy or cell therapy (including CAR-T cell therapy)
- You currently have active graft-versus-host disease (a complication sometimes seen after transplants) or are taking more than 10 mg of prednisone (or a similar steroid medication) daily
- You have received chemotherapy, targeted therapy, or other cancer-directed treatments within the 14 days before screening, or are receiving them during the study
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +886-2-26581868
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]; To determine the RP2D of ARD103; To evaluate overall response rate (ORR)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.